We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) will soon begin a phase 1 clinical trial of Moderna’s variant-specific COVID-19 vaccine candidate, mRNA-1273.351, which has been tailored to better protect against the virus’ South African mutation. Moderna will also conduct trials of its own. Read More
The FDA has published a briefing document ahead of Friday’s advisory panel meeting showing that agency staff have found the promising, single-shot Johnson & Johnson COVID-19 vaccine safe and effective enough for Emergency Use Authorization (EUA). Read More
Senate hearings for HHS Secretary nominee Xavier Becerra, California’s attorney general, concluded Wednesday in the Senate Finance Committee, where Becerra was questioned by senators — and at times heatedly by Republican lawmakers — on a range of healthcare issues including drug pricing, drug shortages and intellectual property protections. Read More
President Biden signed an executive order Wednesday mandating a review of the U.S. supply chain for critical goods, including materials needed for manufacturing COVID-19 products — fulfilling a promise he made on the campaign trail. Read More
As Teva Pharmaceuticals tries to convince the full U.S. Court of Appeals for the Federal Circuit to reconsider its earlier judgment that it has to pay $235.5 million in damages to GlaxoSmithKline (GSK) for patent infringement, oral arguments this week left it unclear whether the final decision will be any different. Read More
While access to cardiovascular drugs in lower-income countries has expanded, a significant gap still exists between access afforded to them and the access enjoyed by higher-income nations when it comes to these medications. Read More
